Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary VAAST platform. The company's tablet vaccines use a non-replicating Ad5 vector to deliver antigens and adjuvants to the small intestine, targeting mucosal and systemic immunity. Pipeline candidates address norovirus, COVID-19, influenza, and HPV-related cervical cancer. No products are currently approved or marketed.
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-13 | 2025-12-31 | 0001437749-26-008023 | EDGAR | 93K words |
| 2025-03-20 | 2024-12-31 | 0001437749-25-008572 | EDGAR | — |
| 2024-03-14 | 2023-12-31 | 0001437749-24-007865 | EDGAR | — |
| 2023-03-15 | 2022-12-31 | 0001437749-23-006688 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001437749-22-004354 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001437749-21-004115 | EDGAR | — |
| 2020-03-19 | 2019-12-31 | 0001437749-20-005683 | EDGAR | — |
| 2019-02-06 | 2018-12-31 | 0001513162-19-000041 | EDGAR | — |
| 2017-09-01 | 2017-06-30 | 0001437749-17-015526 | EDGAR | — |
| 2016-09-13 | 2016-06-30 | 0001437749-16-038645 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001437749-25-034840 | EDGAR | 34K words |
| 2025-08-13 | 2025-06-30 | 0001437749-25-026514 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001437749-25-016459 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001437749-24-034927 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001437749-24-025556 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001437749-24-016236 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001437749-23-030009 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001437749-23-021966 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001437749-23-012560 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001437749-22-026427 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001437749-22-019415 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001437749-22-011554 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-12 | 0001437749-26-007968 | EDGAR | 3K words |
| 2025-12-29 | 0001437749-25-038774 | EDGAR | — |
| 2025-11-13 | 0001437749-25-034829 | EDGAR | — |
| 2025-11-05 | 0001437749-25-033362 | EDGAR | — |
| 2025-10-10 | 0001437749-25-030868 | EDGAR | — |
| 2025-09-19 | 0001437749-25-029485 | EDGAR | — |
| 2025-09-19 | 0001437749-25-029434 | EDGAR | — |
| 2025-09-08 | 0001437749-25-028570 | EDGAR | — |
| 2025-09-02 | 0001437749-25-028167 | EDGAR | — |
| 2025-08-29 | 0001437749-25-028047 | EDGAR | — |
397 total filings indexed. 365 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000072444 |
| Ticker | VXRT |
| Exchange | OTC |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report